Innate Pharma plans Phase 3 lacutamab trial, names new CMO

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL), pending the closing of its strategic partnership with Sobi (Nasdaq Stockholm: SOBI).

The Phase 3 trial is intended to support a planned accelerated approval filing for lacutamab in Sézary syndrome, based on existing TELLOMAK Phase 2 data. The study is designed as an open-label, multicenter, randomized trial in patients with Sézary syndrome and mycosis fungoides who have failed at least one prior systemic therapy.

The partnership with Sobi includes a $75 million upfront payment, payable upon closing, which the company said is expected to extend its projected cash runway through the third quarter of 2027. Closing remains subject to conditions including antitrust clearance. Innate said it continues to explore additional financing opportunities.

Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026, succeeding Sonia Quaratino. Jensen joined Innate Pharma in 2024 as head of clinical pharmacology and has served as global clinical lead for key programs including IPH4502. He holds a medical degree from the University of Cologne and is board certified in Internal Medicine and Clinical Pharmacology. Prior to joining Innate, he held leadership roles at Bayer for more than 16 years, with a focus on oncology and clinical development.

"This is a pivotal moment for Innate," said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. "Following the partnership with Sobi, we plan to advance lacutamab into the TELLOMAK-3 Phase 3 study, marking a major step toward our planned accelerated approval filing based on existing TELLOMAK Phase 2 data."

Lacutamab has received Fast Track and Breakthrough Therapy designations from the FDA, as well as PRIME designation from the EMA, for Sézary syndrome. The drug also holds Orphan Drug designation in both the U.S. and EU for CTCL.

You May Also Be Interested In

• NeOnc Phase 2a brain cancer trial shows 48.9% survival vs. 20% benchmark
• Adamas Trust prices $90M senior notes offering at 9.600%
• NeOnc phase 2a trial of intranasal NEO100 meets primary endpoint